RTOG-9408

A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate

Principal Investigator

David G. McGowan

Status

Disease Site

Genitourinary [GU] Prostate

Phase

III

Developmental Therapeutics

No

Primary Objective

To evaluate whether a combination of Zoladex and flutamide used as cytoreductive agents prior to and during definitive radiation therapy improves overall survival over radiation therapy alone in locally confined carcinomas of the prostate

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Histologically confirmed locally confined adenocarcinoma of the prostate.
Clinical stages T1b-2b.
No involved nodes.
No distant metastases.
Karnofsky performance status > = 70.
No prior antiandrogen therapy (except as allowed by Section 3.1.5), radiation or chemotherapy

Target Accrual

1980